Ranolazine is an anti-ischemic agent which modulates myocardial metabolism. Antianginal.
Ranolazine-d3 Dihydrochloride is the labeled analogue of Ranolazine Dihydrochloride (R122505), an anti-ischemic agent which modulates myocardial metabolism. Antianginal.
Ranolazine-d3 intended for use as an internal standard for the quantification of Ranolazine by GC- or LC-mass spectrometry.
Ranolazine-d3 is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP). Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor.